Literature DB >> 2655687

A double-blind randomized cross-over study of the efficacy and tolerability of nifedipine and nitrendipine in the treatment of mild to moderate hypertension.

A M Heagerty1, J D Swales.   

Abstract

1. In order to examine whether nitrendipine was superior to slow release nifedipine as monotherapy in the treatment of mild to moderate essential hypertension, the two agents were administered to 22 patients in a double-blind randomized cross-over study, incorporating low and titrated dose regimes. 2. Six patients failed to complete the study because of vasodilator side-effects such as headache, flushing and ankle swelling. Three were taking nitrendipine and three took nifedipine and all withdrawals occurred at the introduction of the drug. 3. Both agents reduced blood pressure in the 16 patients who completed the study, and neither agent was superior to the other; mean blood pressure after the placebo phase was 177 +/- 5.5/100 +/- 2.6 mm Hg supine and 175 +/- 5.3/113 +/- 2.4 mm Hg standing. At the end of therapy with nifedipine pressures were 160 +/- 4.0/91 +/- 3.0 mm Hg supine and 158 +/- 4.6/103 +/- 2.7 mm Hg standing. After 8 weeks treatment with nitrendipine blood pressures were 162 +/- 4.4/90 +/- 2.9 mm Hg supine and 161 +/- 6.2/104 +/- 2.7 mm Hg standing. Comparisons of these attained blood pressures on both agents showed no statistically significant differences. 4. Nitrendipine did not appear to be effective on a once daily basis.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2655687      PMCID: PMC1379718          DOI: 10.1111/j.1365-2125.1989.tb05387.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  5 in total

1.  To be taken as directed.

Authors:  M S Gatley
Journal:  J R Coll Gen Pract       Date:  1968-07

2.  Efficacy of nitrendipine as baseline antihypertensive therapy.

Authors:  H Rüddel; R Schmieder; W Langewitz; J Neus; O Wagner; A W von Eiff
Journal:  J Cardiovasc Pharmacol       Date:  1984       Impact factor: 3.105

3.  Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. A cooperative study.

Authors: 
Journal:  JAMA       Date:  1977-01-17       Impact factor: 56.272

4.  The two-period cross-over clinical trial.

Authors:  M Hills; P Armitage
Journal:  Br J Clin Pharmacol       Date:  1979-07       Impact factor: 4.335

5.  Antihypertensive effects on blood pressure at rest and during exercise of calcium antagonists, beta-receptor blockers, and their combination in hypertensive patients.

Authors:  I W Franz; D Wiewel
Journal:  J Cardiovasc Pharmacol       Date:  1984       Impact factor: 3.105

  5 in total
  4 in total

Review 1.  Sustained release nifedipine formulations. An appraisal of their current uses and prospective roles in the treatment of hypertension, ischaemic heart disease and peripheral vascular disorders.

Authors:  D Murdoch; R N Brogden
Journal:  Drugs       Date:  1991-05       Impact factor: 9.546

2.  Comparison of once daily atenolol, nitrendipine and their combination in mild to moderate essential hypertension.

Authors:  D Maclean; E T Mitchell; R Lewis; N Irvine; J S McLay; J McEwen; R R Coulson; N D Slater; T J Fitzsimons; D G McDevitt
Journal:  Br J Clin Pharmacol       Date:  1990-04       Impact factor: 4.335

3.  Comparison of casual, ambulatory and self-measured blood pressure in a study of nitrendipine vs bisoprolol.

Authors:  T Mengden; B Bättig; M Schubert; T Jeck; B Weisser; C Buddeberg; W Vetter
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

4.  Control of blood pressure in hypertensive patients with felodipine extended release or nifedipine retard.

Authors:  W A Littler
Journal:  Br J Clin Pharmacol       Date:  1990-12       Impact factor: 4.335

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.